

Prosidion Ltd

[View the current Prosidion Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/28722-Prosidion+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/28722-Prosidion+Ltd.html>)

Contact Details:

Watlington Road
Oxford
Oxfordshire
OX4 6LT
United Kingdom

Tel: 44 (0)1865 782600
Fax: 44 (0)1865 782601
Email: Info@Prosidion.com

(OSI) Prosidion is the diabetes and obesity business group within OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. (OSI) Prosidion's lead compound PSN9301 is a Dipeptidyl Peptidase IV (DP-IV) inhibitor currently in Phase II clinical trials. PSN357, a glycogen phosphorylase inhibitor, is undergoing Phase IIa clinical studies and PSN010, a glucokinase activator, has recently entered Phase I clinical trials. (OSI) Prosidion owns or has licensing rights to a portfolio of DP-IV medical use patents with claims covering DP-IV as a target for anti-diabetes therapy and the use of combinations of DP-IV inhibitors with other anti-diabetes drugs such as metformin. A number of non-exclusive licenses to the patent estate have been granted to major pharmaceutical companies. (OSI) Prosidion operates through OSI's wholly-owned subsidiary, Prosidion Limited, in Oxford, UK

Recent Publications by Prosidion Ltd:



- [5-HT\(1A\) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.](#)
*The noradrenaline (NA) and serotonin reuptake inhibitor, sibutramine,...*6th June, 2009
Prosidion Research,- Obesity (Silver Spring). 2009 Mar;17(3):467-73. Epub 2008 Dec 11. ([DOI Direct Link](#))
- [SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-\(4-sulfonylphenyl\)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.](#)
*Allosteric activators of the glucose-sensing enzyme glucokinase (GK) are...*30th August, 2008
OSI) Prosidion, Windrush Court, Watlington Road, Oxford OX4 6LT, United- J Med Chem. 2008 Jul 24;51(14):4340-5. Epub 2008 Jun 28. ([DOI Direct Link](#))
- [GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.](#)
*GPR119 is a G protein-coupled receptor expressed predominantly in the...*29th April, 2008

- (OSI) Prosidion,- Br J Pharmacol. 2008 Mar;153 Suppl 1:S76-81. Epub 2007 Nov 26. ([DOI Direct Link](#))
- [PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.](#)
*BACKGROUND AND PURPOSE: Rimonabant (Acomplia, SR141716A), a cannabinoid...*26th February, 2008
 Prosidion Limited, Windrush Court, Oxford, UK.- Br J Pharmacol. 2007 Nov;152(5):805-14. Epub 2007 Jun 25. ([DOI Direct Link](#))
 - [Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.](#)
*AIMS/HYPOTHESIS: We evaluated the insulinotropic and antihyperglycaemic...*18th October, 2007
 (OSI)Prosidion, Windrush Court, Watlington Road, Oxford, UK.- Diabetologia. 2007 Jun;50(6):1277-87. Epub 2007 Apr 6. ([DOI Direct Link](#))
 - [Applying science to drug discovery.](#)
*Scientists and science in the pharmaceutical industry rely heavily on the...*17th June, 2006
 Prosidion Ltd, Watlington Road, Oxford OX4 6LT, UK.- Biochem Soc Trans. 2006 Apr;34(Pt 2):238-42. ([DOI Direct Link](#))
 - [Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.](#)
*The endogenous lipid signaling agent oleoylethanolamide (OEA) has recently...*2nd May, 2006
 (OSI)Prosidion, Windrush Court, Watlington Road, Oxford OX4 6LT, UK.- Cell Metab. 2006 Mar;3(3):167-75. ([DOI Direct Link](#))

Press Releases on Prosidion Ltd:

[2009 Pharma](#)

[ChemOutsourcing Show](#)

[Attendance Up an Astounding 60% Despite Current Recession](#)

3rd June, 2009

Apaporis LLC

LONG BRANCH, N.J., June 3 /PRNewswire/ -- The 2009 Pharma ChemOutsourcing Conference & Exhibition attendance is way up again in 2009 and is poised to shatter the attendance record set in 2008.

[Life Sciences Day of DVC](#)

[Deutsche Venture Capital – Highlights and](#)

1st July, 2004

Dvc

Life Sciences Day of DVC Deutsche Venture Capital – Highlights and Trends in the Biotechno-logy-Sector in Germany 16. July 2004 III. Munich – The third Life Science Day of the DVC has taken

[DVC Deutsche Venture](#)

[Capital achieves a substantial return on the asset](#)

1st January, 1970

Dvc

DVC Deutsche Venture Capital achieves a substantial return on the asset sale of portfolio company Probidrug to Prosidion Ltd. 9th July 2004 Munich – DVC Deutsche Venture Capital, one of Europe



Prosidion Ltd Patents:

- 7582632- [Tri\(cyclo\) substituted amide compounds](#)
- 7262196- [Tri\(cyclo\) substituted amide glucokinase activator compounds](#)
- 7214681- [Tri\(cyclo\) substituted amide compounds](#)
- 7166579- [Prodrugs of DP IV-inhibitors](#)
- 7083933- [Methods for identification of modulators of OSGPR116 activity](#)
- 7060719- [Glutaminyl based DPIV inhibitors](#)
- 7053055- [Compounds of unstable DP IV-inhibitors](#)
- 6890905- [Methods for improving islet signaling in diabetes mellitus and for its prevention](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

